Skip to main content

Table 1 Summary of Target FISH results on 40 patients

From: Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma

No.

Sex/Age

PC%a

BioViewb

Del(17p)/TP53

t(4;14)

t(14;16)

+1q21

Others

1

M/52

26 %

14–16 % (10323–15875)

Neg (230)c

38 % + (74)

Neg (201)

30 % + (180)

 

2

F/80

15 %

3–4 % (9605–13508)

Neg (89)

Neg (61)

Neg (71)

Neg (71)

Normal cytogenetics

3

M/69

12 %

3–4 % (8880–11094)

Neg (84)

Neg (46)g

Neg (40)g

Neg (62)

 

4

M/81

43 %

No record

Neg (253)

Neg (188)

Neg (175)

Neg (200)

5/9/15 60 % + (235)

5

M/64

15 %

58–64 % (11912–17007)

Neg (159)

Neg (153)

Neg (156)g

Neg (155)

5/9/15 Neg (84)

6

M/70

17 %

4–7 % (7132–7616)

Neg (63)

Neg (53)g

Neg (51)g

80 % + (53)

5/9/15 Neg (61)

7

F/52

35 %

8–12 % (7750–8981)

Neg (159)

90 % + (112)g

Neg (102)g

65 % + (167)

Cytogeneticsd: hypodiploid 78.5 %, hyperdiploid 7 %, normal 14.5 %

8

F/72

13 %

42–55 % (11829–14627)

Neg (32)

Neg (35)

Neg (71)

Neg (54)

 

9

F/71

17 %

7–9 % (8667–11174)

Neg (82)

70 % + (54)

Neg (37)

50 % + (65)

Normal cytogenetics

10

M/61

65 %

17–24 % (10289–13997)

Neg (135)

Neg (94)g

Neg (98)g

90 % + (145)

 

11

M/54

15 %

15–22 % (12898–19268)

Neg (141)

80 % + (87)

Neg (84)

Neg (113)

5/9/15 Neg (171)

12

M/47

100 %

50–59 % (10424–12419)

50 % + (132)

Neg (144)g

Neg (107)g

Neg (156)

 

13

M/59

60 %

10–12 % (9514–13412)

Neg (154)

Neg (133)g

Neg (128)g

Neg (140)

t(11;14) 90 %+; normal cytogenetics

14

M/81

22 %

50–52 % (10110–15964)

Neg (140)

60 % + (78)g

Neg (111)g

85 % + (172)

5/9/15 Neg (101)

15

F/67

45 %

21–27 % (6066–7366)

Neg (163)

90 % + (145)

Neg (136)

85 % + (183)

5/9/15 Neg (157)

16

M/58

No record

8–9 % (6666–8923)

Neg (250)

Neg (192)g

Neg (188)g

Neg (224)

t(11;14) 25 % + (228)

17

F/70

51 %

13–17 % (7469–8551)

Neg (183)

Neg (137)g

Neg (118)g

85 % + (162)

Normal cytogenetics

18

F/53

23 %

10 % (2719–4195)

Neg (198)

Neg (146)

Neg (80)

Neg (106)

5/9/15 Neg (87)

19

M/76

70 %

6–7 % (4145–5686)

Neg (108)

Neg (89)

Neg (102)

Neg (101)

IgH Neg (71)

20

M/61

49 %

17–19 % (4210–5352)

Neg (170)

Neg (126)

Neg (119)

85 % + (172)

 

21

M/61

20 %

24–29 % (9895–11736)

Neg (145)

Neg (122)

Neg (87)

Neg (142)

Normal cytogenetics

22

F/48

59 %

6–9 % (6942–7583)

40 % + (172)

65 % + (110)

Neg (111)

55 % + (154)

Normal cytogenetics

23

F/56

100 %

3–8 % (4400–6203)

Neg (123)

Neg (149)g

Neg (118)

65 % + (158)

 

24

F/55

84 %

3–6 % (9304–10362)

Neg (141)

Neg (148)

Neg (107)

Neg (82)

t(11;14) 85 % + (121)

25

M/52

74 %

11–23 % (10024–12394)

Neg (158)

85 % + (100)

Neg (135)g

90 % + (162)

Cytogeneticse: hypodiploid clone, der(4)t(1;4)(q21;p16) and add(7p)

26

F/56

35 %

11–17 % (10247–12375)

Neg (100)

Neg (166)

Neg (140)g

Neg (117)

 

27

F/55

73 %

10–17 % (3419–5581)

Neg (186)

Neg (167)

Neg (142)

Neg (171)

 

28

F/57

15 %

6–8 % (5191–6330)

Neg (102)

Neg (122)

Neg (102)

Neg (100)

 

29

F/69

16 %

25–32 % (7923–12371)

Neg (172)

Neg (143)g

Neg (104)g

Neg (173)

 

30

M/58

19 %

3–5 % (6385–8924)

Neg (213)

Neg (169)

Neg (154)

Neg (208)

 

31

F/66

29 %

7–11 % (7383–9153)

Neg (149)

70 % + (73)

Neg (108)g

80 % + (127)

 

32

F/56

15 %

7–12 % (11256–13079)

Neg (146)

Neg (117)g

Neg (93)

Neg (150)

 

33

M/64

13 %

4–6 % (11082–12940)

Neg (118)

Neg (100)

Neg (98)

Neg (101)

t(11;14) 40 % + (149); cytogeneticsf: loss of Y chromosome

34

F/67

21 %

6–13 % g11872–14598)

Neg (159)

70 % + (104)

Neg (118)g

95 % + (136)

 

35

F/89

12 %

3–5 % (11793–14289)

Neg (121)

Neg (134)

Neg (102)

Neg (102)

Normal cytogenetics

36

F/50

56 %

14–17 % (10614–13489)

Neg (140)

Neg (143)

Neg (111)

60 % + (137)

 

37

M/60

50 %

24–27 % (10633–13622)

Neg (165)

Neg (121)

Neg (117)

83 % + (143)

 

38

M/79

20 %

6–10 % (13896–15969)

Neg (125)

Neg (96)

Neg (121)g

80 % + (144)

80 % trisomy TP53

39

F/67

53 %

32–38 % (13807–17047)

Neg (162)

63 % + (123)

Neg (103)

63 % + (104)

 

40

M/69

57 %

6–13 % (12778–15272)

Neg (158)

Neg (127)

Neg (148)

Neg (158)

 
  1. Key:
  2. aThe PC% refers to the plasma cell percentage in the bone marrow aspirate as enumerated on microscopic examination
  3. bThe BioView data refers to the percentage of cells in the plasma cell category as recognized by the automated image capture and analysis system before manual re-classification. The number in the parentheses refers to the total number of cells analyzed by the automated image capture and analysis system on the slide. Both are reported as a range of figures obtained from the 4 slides
  4. cThe number in parenthesis is the actual number of re-classified plasma cells with optimal FISH signals on which the positive or negative result is based. This figure is also indicated on the pathology report for each FISH probe
  5. d26 ~ 45,XX,t(4;14)(p16;q32)[33]/48 ~ 159,XX[3]/46,XX[6]
  6. e43 ~ 44,XY,+3[2],der(4)t(1;4)(q21;p16)[2],add(7)(p13)[2],+7 ~ 8mar[2][cp2]/46,XY[4]
  7. f45,X,-Y[3]/46,XY[15]
  8. gDenotes the incidental finding of secondary abnormalities i.e. monosomy of deletion of chromosomes 4, 14 or 16; trisomy or amplification of chromosomes 4, 14 or 16